|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Eberelbin |
Iran |
|
Eunexon |
Pérou |
|
Eurovinorelbin |
Allemagne |
|
Navelbin |
Hongrie |
|
Navelbine |
Allemagne, Arabie Saoudite, Argentine, Australie, Autriche, Belgique, Chili, Colombie, Danemark, Egypte, Emirats Arabes Unis , Espagne, Etats Unis d’Amérique, Finlande, France, Grande Bretagne, Grèce, Inde, Iran, Irlande, Islande, Italie, Luxembourg, Malaisie, Mexique, Norvège, Nouvelle Zélande, Pérou, Pologne, Portugal, Roumanie, Suède, Suisse, Tunisie, Turquie |
|
Navildez |
Mexique |
|
Navin |
Allemagne |
|
Navirel |
Allemagne, Norvège, Suède |
|
Okabine |
Pérou |
|
Relbinalur |
Suède |
|
Renovel |
Turquie |
|
Setroxin |
Mexique |
|
Sulcoline |
Argentine |
|
Tarckorel |
Mexique, Pérou |
|
Vieby |
Mexique |
|
Viessia |
Colombie, Mexique, Vénézuela |
|
Vilne |
Argentine, Equateur, Pérou |
|
Vinarine |
Argentine, Pérou, Vénézuela |
|
Vinelbine |
Malaisie |
|
Vinilex |
Mexique |
|
Vinkebir |
Argentine, Pérou |
|
Vinobina |
Colombie |
|
Vinobur |
Suède |
|
Vinolbin |
Allemagne |
|
Vinorel |
Argentine, Pérou |
|
Vinorelbin |
Allemagne, Autriche, Belgique, Equateur, Islande, Norvège, Roumanie, Suède, Suisse |
|
Vinorelbina |
Colombie, Equateur, Espagne, Mexique, Pérou, Roumanie |
|
Vinorelbine |
Argentine, Belgique, Canada, Etats Unis d’Amérique, Grande Bretagne, Iran, Nouvelle Zélande, Suisse |
|
Vinorgen |
Chili, Pérou |
|
Zinavin |
Colombie |
|
|
 |
 |
Bibliographie : Vinorelbine tartrate |
|
|
Type |
Source |
| 84 |
Revue |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 144 |
Revue |
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285. |
| 182 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 251 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 307 |
Revue |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 905 |
Revue |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1070 |
Revue |
Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891. |
| 1413 |
Revue |
Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1501 |
Revue |
Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121. |
| 1520 |
Laboratoire |
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001 |
| 1625 |
Revue |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Revue |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 2260 |
Laboratoire |
Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007 |
| 3128 |
Laboratoire |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3474 |
Laboratoire |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3595 |
Laboratoire |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3641 |
Laboratoire |
Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011 |
| 3644 |
Laboratoire |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3838 |
Laboratoire |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4471 |
Laboratoire |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
|
|
